1. Introduction

Langerhans cell histiocytosis (LCH), named by the Histiocyte Society (HS) in 1987, previously identified as histiocytosis X (HX), is a hyperplastic cellular disease of undetermined causes [1]. LCH is categorized by an uncontrolled clonal proliferation of Langerhans cells, which is a part of the human mononuclear phagocytic system [2].

Usually characterized by single (monostotic) or multiple (polyostotic) osteolytic bone lesions, solitary or multiple lymph node involvements associated to ulcerations of skin and soft tissues, and involvement of the central nervous system (CNS) [3].

Bones, excluding hands and feet, are the most commonly affected organs (80%) with 75% unifocal lesions and painful soft tissue swelling [3–5]. LCH is divided into 3 types: acute, disseminated, chronic, multifocal, and chronic focal [6]. Subdivisions for localized and disseminated LCH are reported by the blood group in 2016 [2]. Treatment modalities for adults have never been clarified by a clinical trial and the clinical reports deliver minimal data on the efficiency of various adopted treatments, which include surgery/curettage, steroids, low-dose radiotherapy (RT), and various chemotherapy regimens [7–14].

In this manuscript, we reported a case of isolated osteolytic lesions related to HLC observed in both jaws and treated with fractionated stereotactic low-dose RT with a 5-year follow-up period.
Figure 1: (a) Gingival ulcer proliferative growth in relation with the restored right maxillary molars. (b) 2D panoramic radiograph showing the unilocular radiolucency in the maxilla and the mandible. (c) Axial images of the CT scan exposed the presence of radiolucency in the maxilla with cortical bone deterioration. (d) Axial images of the CT scan displaying a well-defined localized radiolucency in the body of the mandible. (e) The excised tissue after tooth extraction. (f) Histopathology of Langerhans cell histiocytosis: prominent histiocytes with abundant cytoplasm against the background of mixed population of eosinophils and multinucleated giant cells (HE ×10).
2. Case Report

A 42-year-old male has been oriented to our department, complaining of unilateral facial swelling with persistent pain, one year after extraction of the left mandibular premolars. Additionally, he presented a gingiva swelling in the right maxilla related to a fixed bridge.

The clinical exam showed palpable lymph node, nontender, freely movable on the left submandibular area, and intraoral examination revealed a painful buccal cortical expansion in relation to the first and second mandibular molars. In the maxilla, a gingival ulcer proliferative growth in relation to the restored right molars was observed with a mobility type II (Figure 1(a)). A 2D panoramic radiograph was taken and showed a well-defined unilocular radiolucency in the apical area of the second maxillary molar with no extension to the maxillary sinus. In the left side of the mandible, two well-defined radiolucencies were noted, the first in relation to the mesial root of the first molar and the second on the mandibular body apically to the second molar (Figure 1(b)).

The axial images of the CT scan revealed the presence of radiolucency in the maxilla with cortical bone deterioration buccally and palatally and in the mandible and a well-defined localized radiolucency in the body of the mandible (Figures 1(c) and 1(d)).
Based on clinical and radiological findings, the differential diagnosis suggested was a radicular cyst, osteomyelitis, primary bone tumor, lymphoma, and LCH.

The extraction of the maxillary molars was proposed by us and approved by the patient. Under loco-regional analgesia, the two teeth were extracted, and the excised tissue was sent for histological evaluation (Figure 1(e)). The result came out with an LCH diagnosis (Figure 1(f)).

Histological examination exposed cellular proliferation characterized by unique reniform nuclei with eosinophilic cytoplasm representing Langerhans cells, in a stroma with numerous acute and chronic inflammatory infiltrate cells.

The patient was oriented to the internal medicine department to determine the degree of the disorder and to discuss the appropriate treatment protocol.

Hematological explorations displayed a significant increase in eosinophil count by 12%.

An entire body CT scan was accomplished which showed no evidence of lesions in other organs. Bone scintigraphy was completed and confirms that the lesions are limited in the right maxilla and on the left mandible (Figures 2(a) and 2(b)).

The treatment plan we proposed and accepted by the patient was the extraction of all the teeth in the affected region followed by fractionated stereotactic low-dose RT after two months (Figure 2(c)).

2.1. Radiation Therapy. A 6-megavolt linear accelerator was used with a 0.5 mm precision of its isocenter.

A custom-made rigid mask was fabricated and used for accurate immobilization of the head as described by Al Salah and El Hajj [15]. The objective of the custom-made rigid mask is to stabilize the head during the radiotherapy sessions (Figures 3(a) and 3(b)).

3D treatment planning is prepared using the CT scan images fed into the planning system (Figure 3(c)). The target volume is determinate and verified by the radiation oncologist. Dosimetry planning is organized around three isocenters for the mandible and a single isocenter for the right maxillary sinus. Planning has been done to avoid the parotid glands.

Each of the right maxilla and the left mandible received 24 Gy in 16 fractions (1.5 Gy in each session) during 32 days.

Preventive and palliative treatments included dexamethasone cream applied twice daily to the irradiated skin and mouth baths of a mixture of bicarbonate, antifungal gel, and local anesthetic application 3 times per day. Moreover, customized tooth adapted aligners were fabricated before the RT sessions for fluoride gel application for 5 minutes every day before, during, and after the end of RT treatment for 3 months. The patient presented a

Figure 3: (a) Custom-made rigid mask. (b) Patient wearing the stabilisation mask. (c) 3D treatment planning is done using the CT scan images.
grade two mucositis during the treatment and was treated 
with corticosteroid oral rinses beside the good oral 
hygiene.
Xerostomia grade two has been experienced during the 
last two weeks of irradiation, but complete recovery has been 
reached one month after the treatment.
The patient was followed up in the beginning, every 6 
months yearly. Complete remission was achieved clinically 
and radiologically after one year (Figures 4(a)–4(c)).
The panoramic X-ray and CBCT after 5 years confirm 
the complete bone healing process (Figures 5(a)–5(c)).

3. Discussion
Several treatment modalities have been reported for solitary 
and polyostotic bone lesions such as curettage or excision 
[7, 9], intralesion steroid injection [10], chemotherapy treat-
ment with vinblastine, and prednisone [9] or cytosine arabi-
noside [8], and low-dose RT [11–14]. The effectivity of RT in 
LCH has been widely reported, but several elements should 
be respected such as the age of patients, the possibility of radiogenic malignancies, and the semibenign character of 
the disease [11–14].
It is used as a single treatment option or in combination with chemotherapy, surgery, or steroid injections [7–14].

The mechanism of action induced by ionizing radiation on target cells remains unclear [12, 13].

In adults, the recommended doses range between 10 and 45 Gy and should be supplied in fractions of 1–2 Gy by session to respect the capacity for tissue repair mechanisms [11–13].

Olschewski and Seegenschmiedt (2006), evaluated 89 LCH patients treated by RT with fractionation and 2 Gy as a median single dose and 24 Gy as median total, 91% got a local remission of the treated lesions, 77.5% had a complete remission, and only 9% developed recurrence [11].

Kriz et al. (2013) published the results of a retrospective analysis performed by the German Cooperative Group for Benign Diseases where 80 patients suffering from LCH were treated with RT during the last past 45 years and found that 77% achieved a complete remission with a median follow-up period of 54 months. They used RT with fractionation of a median total dose of 15 Gy, and the median single fraction was 2 Gy [12].

The treatment protocol proposed to our patient was very mild toxicity.

Healing of soft tissue and bone was observed over the 5-year follow-up.

4. Conclusion

LCH is an idiopathic benign disorder touching both genders at any age and can affect one or more organs. It is usually characterized by monostotic or polyostotic osteolytic bone lesions.

There is no consensus treatment for the management of these lesions. Fractionated stereotactic low-dose RT is deemed to be an efficient option for LCH treatment alone or combined with other treatment modalities.

Data Availability

All the data are presented in the paper.

Ethical Approval

Ethical approval is not necessary for case report.

Consent

Patient signed the consent.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

The author thanks Pr. Saad Khairalah, Pr. Labib, el Hajj, and Pr. Dani Gergis for their valuable help and assistance.
References

[1] T. Chu, G. J. D’Angio, B. E. Favara, S. Ladisch, M. Nesbit, and J. Pritchard, “Histiocytosis syndromes in children. Writing Group of the Histiocyte Society,” Lancet, vol. 2, no. 8549, pp. 41–42, 1987.

[2] J. F. Emile, O. Abla, S. Fraitag et al., “Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages,” Blood, vol. 127, no. 22, pp. 2672–2681, 2016.

[3] J. Krooks, M. Minkov, and A. G. Weatherall, “Langerhans cell histiocytosis in children: history, classification, pathobiology, clinical manifestations, and prognosis,” Journal of the American Academy of Dermatology, vol. 78, no. 6, pp. 1035–1044, 2018.

[4] M. Aricò, I. Astigarraga, J. Braier et al., “Lack of bone lesions at diagnosis is associated with inferior outcome in multisystem langerhans cell histiocytosis of childhood,” British Journal of Haematology, vol. 169, no. 2, pp. 241–248, 2015.

[5] S. Khung, J. F. Budzik, E. Amzallag-Bellenger et al., “Skeletal involvement in Langerhans cell histiocytosis,” Insights Into Imaging, vol. 4, no. 5, pp. 569–579, 2013.

[6] C. Lian, Y. Lu, and S. Shen, “Langerhans cell histiocytosis in adults: a case report and review of the literature,” Oncotarget, vol. 7, no. 14, pp. 18678–18683, 2016.

[7] M. Kobayashi and A. Tojo, “Langerhans cell histiocytosis in adults: advances in pathophysiology and treatment,” Cancer Science, vol. 109, no. 12, pp. 3707–3713, 2018.

[8] M. A. Cantu, P. J. Lupo, M. Bilgi, M. J. Hicks, C. E. Allen, and K. L. McClain, “Optimal therapy for adults with Langerhans cell histiocytosis bone lesions,” PLoS One, vol. 7, no. 8, article e43257, 2012.

[9] F. Gargano, J. J. Welch, P. M. Klinge, S. R. Sullivan, and H. O. Taylor, “Langerhans cell histiocytosis in the pediatric population,” The Journal of Craniofacial Surgery, vol. 30, no. 4, pp. 1191–1193, 2019.

[10] T. F. Putters, J. G. de Visscher, A. van Veen, and F. K. Spijkervet, “Intralesional infiltration of corticosteroids in the treatment of localised langerhans’ cell histiocytosis of the mandible: Report of known cases and three new cases,” International Journal of Oral and Maxillofacial Surgery, vol. 34, no. 5, pp. 571–575, 2005.

[11] T. Olschewski and M. H. Seegenschmiedt, “Radiotherapy for bony manifestations of Langerhans cell histiocytosis. Review and proposal for an international registry,” Strahlentherapie und Onkologie, vol. 182, no. 2, pp. 72–79, 2006.

[12] J. Kriz, H. T. Eich, F. Bruns et al., “Radiotherapy in langerhans cell histiocytosis - a rare indication in a rare disease,” Radiation Oncology, vol. 8, no. 1, p. 233, 2013.

[13] R. Kotecha, R. Venkatramani, R. F. Jubran, A. Arkader, A. J. Olch, and K. Wong, “Clinical outcomes of radiation therapy in the management of Langerhans cell histiocytosis,” American journal of clinical oncology, vol. 37, no. 6, pp. 592–596, 2014.

[14] J. Laird, J. Ma, K. Chau et al., “Outcome after radiation therapy for langerhans cell histiocytosis is dependent on site of involvement,” International Journal of Radiation Oncology • Biology • Physics, vol. 100, no. 3, pp. 670–678, 2018.

[15] A. Al Salah and L. El Hajj, “The use of custom- made masks in stereotactic radiation therapy,” Physica Medica, vol. 17, no. 2, p. 111, 2001.